Non–HDL Cholesterol, Apolipoproteins A-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women
CONTEXT Current guidelines for cardiovascular risk detection are controversial with regard to the clinical utility of different lipid measures, non–high-density lipoprotein cholesterol (non–HDL-C), lipid ratios, apolipoproteins, and C-reactive protein (CRP). OBJECTIVE To directly compare the clinica...
Saved in:
Published in | JAMA : the journal of the American Medical Association Vol. 294; no. 3; pp. 326 - 333 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Chicago, IL
American Medical Association
20.07.2005
|
Subjects | |
Online Access | Get full text |
ISSN | 0098-7484 1538-3598 1538-3598 |
DOI | 10.1001/jama.294.3.326 |
Cover
Abstract | CONTEXT Current guidelines for cardiovascular risk detection are controversial
with regard to the clinical utility of different lipid measures, non–high-density
lipoprotein cholesterol (non–HDL-C), lipid ratios, apolipoproteins,
and C-reactive protein (CRP). OBJECTIVE To directly compare the clinical utility of total cholesterol, low-density
lipoprotein cholesterol (LDL-C), HDL-C, non–HDL-C, apolipoproteins A-I
and B100, high-sensitivity CRP, and the ratios of total cholesterol
to HDL-C, LDL-C to HDL-C, apolipoprotein B100 to apolipoprotein
A-I, and apolipoprotein B100 to HDL-C as predictors of future cardiovascular
events in women. DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study of 15 632 initially healthy US women aged
45 years or older (interquartile range, 48-59 years) who were enrolled between
November 1992 and July 1995. All participants were followed up over a 10-year
period for the occurrence of future cardiovascular events. MAIN OUTCOME MEASURE Hazard ratios (HRs) and 95% confidence intervals (CIs) for first-ever
major cardiovascular events (N = 464) according to baseline levels
of each biomarker. RESULTS After adjustment for age, smoking status, blood pressure, diabetes,
and body mass index, the HRs for future cardiovascular events for those in
the extreme quintiles were 1.62 (95% CI, 1.17-2.25) for LDL-C, 1.75 (95% CI,
1.30-2.38) for apolipoprotein A-I, 2.08 (95% CI, 1.45-2.97) for total cholesterol,
2.32 (95% CI, 1.64-3.33) for HDL-C, 2.50 (95% CI, 1.68-3.72) for apolipoprotein
B100, 2.51 (95% CI, 1.69-3.72) for non–HDL-C, and 2.98 (95%
CI, 1.90-4.67) for high-sensitivity CRP (P<.001
for trend across all quintiles). The HRs for the lipid ratios were 3.01 (95%
CI, 2.01-4.50) for apolipoprotein B100 to apolipoprotein A-I, 3.18
(95% CI, 2.12-4.75) for LDL-C to HDL-C, 3.56 (95% CI, 2.31-5.47) for apolipoprotein
B100 to HDL-C, and 3.81 (95% CI, 2.47-5.86) for the total cholesterol
to HDL-C (P<.001 for trend across all quintiles).
The correlation coefficients between high-sensitivity CRP and the lipid parameters
ranged from −0.33 to 0.15, and the clinical cut points for CRP of less
than 1, 1 to 3, and higher than 3 mg/L provided prognostic information on
risk across increasing levels of each lipid measure and lipid ratio. CONCLUSIONS Non–HDL-C and the ratio of total cholesterol to HDL-C were as
good as or better than apolipoprotein fractions in the prediction of future
cardiovascular events. After adjustment for age, blood pressure, smoking,
diabetes, and obesity, high-sensitivity CRP added prognostic information beyond
that conveyed by all lipid measures. |
---|---|
AbstractList | Current guidelines for cardiovascular risk detection are controversial with regard to the clinical utility of different lipid measures, non-high-density lipoprotein cholesterol (non-HDL-C), lipid ratios, apolipoproteins, and C-reactive protein (CRP).CONTEXTCurrent guidelines for cardiovascular risk detection are controversial with regard to the clinical utility of different lipid measures, non-high-density lipoprotein cholesterol (non-HDL-C), lipid ratios, apolipoproteins, and C-reactive protein (CRP).To directly compare the clinical utility of total cholesterol, low-density lipoprotein cholesterol (LDL-C), HDL-C, non-HDL-C, apolipoproteins A-I and B(100), high-sensitivity CRP, and the ratios of total cholesterol to HDL-C, LDL-C to HDL-C, apolipoprotein B(100) to apolipoprotein A-I, and apolipoprotein B(100) to HDL-C as predictors of future cardiovascular events in women.OBJECTIVETo directly compare the clinical utility of total cholesterol, low-density lipoprotein cholesterol (LDL-C), HDL-C, non-HDL-C, apolipoproteins A-I and B(100), high-sensitivity CRP, and the ratios of total cholesterol to HDL-C, LDL-C to HDL-C, apolipoprotein B(100) to apolipoprotein A-I, and apolipoprotein B(100) to HDL-C as predictors of future cardiovascular events in women.Prospective cohort study of 15,632 initially healthy US women aged 45 years or older (interquartile range, 48-59 years) who were enrolled between November 1992 and July 1995. All participants were followed up over a 10-year period for the occurrence of future cardiovascular events.DESIGN, SETTING, AND PARTICIPANTSProspective cohort study of 15,632 initially healthy US women aged 45 years or older (interquartile range, 48-59 years) who were enrolled between November 1992 and July 1995. All participants were followed up over a 10-year period for the occurrence of future cardiovascular events.Hazard ratios (HRs) and 95% confidence intervals (CIs) for first-ever major cardiovascular events (N = 464) according to baseline levels of each biomarker.MAIN OUTCOME MEASUREHazard ratios (HRs) and 95% confidence intervals (CIs) for first-ever major cardiovascular events (N = 464) according to baseline levels of each biomarker.After adjustment for age, smoking status, blood pressure, diabetes, and body mass index, the HRs for future cardiovascular events for those in the extreme quintiles were 1.62 (95% CI, 1.17-2.25) for LDL-C, 1.75 (95% CI, 1.30-2.38) for apolipoprotein A-I, 2.08 (95% CI, 1.45-2.97) for total cholesterol, 2.32 (95% CI, 1.64-3.33) for HDL-C, 2.50 (95% CI, 1.68-3.72) for apolipoprotein B(100), 2.51 (95% CI, 1.69-3.72) for non-HDL-C, and 2.98 (95% CI, 1.90-4.67) for high-sensitivity CRP (P<.001 for trend across all quintiles). The HRs for the lipid ratios were 3.01 (95% CI, 2.01-4.50) for apolipoprotein B(100) to apolipoprotein A-I, 3.18 (95% CI, 2.12-4.75) for LDL-C to HDL-C, 3.56 (95% CI, 2.31-5.47) for apolipoprotein B(100) to HDL-C, and 3.81 (95% CI, 2.47-5.86) for the total cholesterol to HDL-C (P<.001 for trend across all quintiles). The correlation coefficients between high-sensitivity CRP and the lipid parameters ranged from -0.33 to 0.15, and the clinical cut points for CRP of less than 1, 1 to 3, and higher than 3 mg/L provided prognostic information on risk across increasing levels of each lipid measure and lipid ratio.RESULTSAfter adjustment for age, smoking status, blood pressure, diabetes, and body mass index, the HRs for future cardiovascular events for those in the extreme quintiles were 1.62 (95% CI, 1.17-2.25) for LDL-C, 1.75 (95% CI, 1.30-2.38) for apolipoprotein A-I, 2.08 (95% CI, 1.45-2.97) for total cholesterol, 2.32 (95% CI, 1.64-3.33) for HDL-C, 2.50 (95% CI, 1.68-3.72) for apolipoprotein B(100), 2.51 (95% CI, 1.69-3.72) for non-HDL-C, and 2.98 (95% CI, 1.90-4.67) for high-sensitivity CRP (P<.001 for trend across all quintiles). The HRs for the lipid ratios were 3.01 (95% CI, 2.01-4.50) for apolipoprotein B(100) to apolipoprotein A-I, 3.18 (95% CI, 2.12-4.75) for LDL-C to HDL-C, 3.56 (95% CI, 2.31-5.47) for apolipoprotein B(100) to HDL-C, and 3.81 (95% CI, 2.47-5.86) for the total cholesterol to HDL-C (P<.001 for trend across all quintiles). The correlation coefficients between high-sensitivity CRP and the lipid parameters ranged from -0.33 to 0.15, and the clinical cut points for CRP of less than 1, 1 to 3, and higher than 3 mg/L provided prognostic information on risk across increasing levels of each lipid measure and lipid ratio.Non-HDL-C and the ratio of total cholesterol to HDL-C were as good as or better than apolipoprotein fractions in the prediction of future cardiovascular events. After adjustment for age, blood pressure, smoking, diabetes, and obesity, high-sensitivity CRP added prognostic information beyond that conveyed by all lipid measures.CONCLUSIONSNon-HDL-C and the ratio of total cholesterol to HDL-C were as good as or better than apolipoprotein fractions in the prediction of future cardiovascular events. After adjustment for age, blood pressure, smoking, diabetes, and obesity, high-sensitivity CRP added prognostic information beyond that conveyed by all lipid measures. CONTEXT Current guidelines for cardiovascular risk detection are controversial with regard to the clinical utility of different lipid measures, non–high-density lipoprotein cholesterol (non–HDL-C), lipid ratios, apolipoproteins, and C-reactive protein (CRP). OBJECTIVE To directly compare the clinical utility of total cholesterol, low-density lipoprotein cholesterol (LDL-C), HDL-C, non–HDL-C, apolipoproteins A-I and B100, high-sensitivity CRP, and the ratios of total cholesterol to HDL-C, LDL-C to HDL-C, apolipoprotein B100 to apolipoprotein A-I, and apolipoprotein B100 to HDL-C as predictors of future cardiovascular events in women. DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study of 15 632 initially healthy US women aged 45 years or older (interquartile range, 48-59 years) who were enrolled between November 1992 and July 1995. All participants were followed up over a 10-year period for the occurrence of future cardiovascular events. MAIN OUTCOME MEASURE Hazard ratios (HRs) and 95% confidence intervals (CIs) for first-ever major cardiovascular events (N = 464) according to baseline levels of each biomarker. RESULTS After adjustment for age, smoking status, blood pressure, diabetes, and body mass index, the HRs for future cardiovascular events for those in the extreme quintiles were 1.62 (95% CI, 1.17-2.25) for LDL-C, 1.75 (95% CI, 1.30-2.38) for apolipoprotein A-I, 2.08 (95% CI, 1.45-2.97) for total cholesterol, 2.32 (95% CI, 1.64-3.33) for HDL-C, 2.50 (95% CI, 1.68-3.72) for apolipoprotein B100, 2.51 (95% CI, 1.69-3.72) for non–HDL-C, and 2.98 (95% CI, 1.90-4.67) for high-sensitivity CRP (P<.001 for trend across all quintiles). The HRs for the lipid ratios were 3.01 (95% CI, 2.01-4.50) for apolipoprotein B100 to apolipoprotein A-I, 3.18 (95% CI, 2.12-4.75) for LDL-C to HDL-C, 3.56 (95% CI, 2.31-5.47) for apolipoprotein B100 to HDL-C, and 3.81 (95% CI, 2.47-5.86) for the total cholesterol to HDL-C (P<.001 for trend across all quintiles). The correlation coefficients between high-sensitivity CRP and the lipid parameters ranged from −0.33 to 0.15, and the clinical cut points for CRP of less than 1, 1 to 3, and higher than 3 mg/L provided prognostic information on risk across increasing levels of each lipid measure and lipid ratio. CONCLUSIONS Non–HDL-C and the ratio of total cholesterol to HDL-C were as good as or better than apolipoprotein fractions in the prediction of future cardiovascular events. After adjustment for age, blood pressure, smoking, diabetes, and obesity, high-sensitivity CRP added prognostic information beyond that conveyed by all lipid measures. Current guidelines for cardiovascular risk detection are controversial with regard to the clinical utility of different lipid measures, non-high-density lipoprotein cholesterol (non-HDL-C), lipid ratios, apolipoproteins, and C-reactive protein (CRP). To directly compare the clinical utility of total cholesterol, low-density lipoprotein cholesterol (LDL-C), HDL-C, non-HDL-C, apolipoproteins A-I and B(100), high-sensitivity CRP, and the ratios of total cholesterol to HDL-C, LDL-C to HDL-C, apolipoprotein B(100) to apolipoprotein A-I, and apolipoprotein B(100) to HDL-C as predictors of future cardiovascular events in women. Prospective cohort study of 15,632 initially healthy US women aged 45 years or older (interquartile range, 48-59 years) who were enrolled between November 1992 and July 1995. All participants were followed up over a 10-year period for the occurrence of future cardiovascular events. Hazard ratios (HRs) and 95% confidence intervals (CIs) for first-ever major cardiovascular events (N = 464) according to baseline levels of each biomarker. After adjustment for age, smoking status, blood pressure, diabetes, and body mass index, the HRs for future cardiovascular events for those in the extreme quintiles were 1.62 (95% CI, 1.17-2.25) for LDL-C, 1.75 (95% CI, 1.30-2.38) for apolipoprotein A-I, 2.08 (95% CI, 1.45-2.97) for total cholesterol, 2.32 (95% CI, 1.64-3.33) for HDL-C, 2.50 (95% CI, 1.68-3.72) for apolipoprotein B(100), 2.51 (95% CI, 1.69-3.72) for non-HDL-C, and 2.98 (95% CI, 1.90-4.67) for high-sensitivity CRP (P<.001 for trend across all quintiles). The HRs for the lipid ratios were 3.01 (95% CI, 2.01-4.50) for apolipoprotein B(100) to apolipoprotein A-I, 3.18 (95% CI, 2.12-4.75) for LDL-C to HDL-C, 3.56 (95% CI, 2.31-5.47) for apolipoprotein B(100) to HDL-C, and 3.81 (95% CI, 2.47-5.86) for the total cholesterol to HDL-C (P<.001 for trend across all quintiles). The correlation coefficients between high-sensitivity CRP and the lipid parameters ranged from -0.33 to 0.15, and the clinical cut points for CRP of less than 1, 1 to 3, and higher than 3 mg/L provided prognostic information on risk across increasing levels of each lipid measure and lipid ratio. Non-HDL-C and the ratio of total cholesterol to HDL-C were as good as or better than apolipoprotein fractions in the prediction of future cardiovascular events. After adjustment for age, blood pressure, smoking, diabetes, and obesity, high-sensitivity CRP added prognostic information beyond that conveyed by all lipid measures. |
Author | Cook, Nancy R Bradwin, Gary Rifai, Nader Buring, Julie E Ridker, Paul M |
Author_xml | – sequence: 1 givenname: Paul M surname: Ridker fullname: Ridker, Paul M – sequence: 2 givenname: Nader surname: Rifai fullname: Rifai, Nader – sequence: 3 givenname: Nancy R surname: Cook fullname: Cook, Nancy R – sequence: 4 givenname: Gary surname: Bradwin fullname: Bradwin, Gary – sequence: 5 givenname: Julie E surname: Buring fullname: Buring, Julie E |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16948648$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16030277$$D View this record in MEDLINE/PubMed |
BookMark | eNpNkc1uFDEMxyNURLeFKxIXlAucdpZkksnHcZnSD2kLaAFxXHkniUiZSYZkBokb78CB9-uTENQtwhfb8s-2_vYJOgoxWISeUrKihNBXNzDAqtZ8xVasFg_QgjZMVazR6ggtCNGqklzxY3SS8w0pRpl8hI6pIIzUUi7Q77cx3P78dXm2we2X2Ns82RT7JV6PsfdjHFOcrA8Zr6srDMHg12XrEn-YSgzJ4I0fvcHXFvKcbF4e8i1MPpbsb0O7fY8h463PX_E5dFNMGbuYcFvaffwOuZt7SPjM5zLEYh_w5zjY8Bg9dNBn--TgT9Gn8zcf28tq8-7iql1vKqgbNlVM6T21TgphaWckkbUwwIxjRBjRMSr2zGgAwrpGubrRznAuHTfcOQLUaXaKXt7NLUq_zUX-bvC5s30PwcY574QijZZSFvD5AZz3gzW7MfkB0o_d_SkL8OIAFE3QuwSh8_k_TnMluCrcszuufO5ftSa0bgj7A-GYjSg |
ContentType | Journal Article |
Copyright | 2005 INIST-CNRS |
Copyright_xml | – notice: 2005 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1001/jama.294.3.326 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-3598 |
EndPage | 333 |
ExternalDocumentID | 16030277 16948648 201250 |
Genre | Research Support, U.S. Gov't, P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GroupedDBID | --- -ET -~X .55 .GJ .XZ 0R~ 0WA 186 18M 1KJ 1VV 29J 2CT 2FS 2KS 2WC 354 39C 4.4 53G 5GY 5RE 6TJ 85S AAIKC AAMNW AAQQT AAWTL AAYOK ABCQX ABEFU ABEHJ ABIVO ABOCM ABPMR ABPPZ ABRSH ABWJO ACAHW ACGFS ACNCT ACPRK ADBBV ADUKH ADXHL AETEA AFCHL AFFNX AFHKK AFRAH AGFXO AGHSJ AHMBA AI. ALMA_UNASSIGNED_HOLDINGS AMJDE ANMPU ARBJA BKOMP BRYMA C45 CJ0 CS3 EAM EBS EJD EMOBN EX3 F5P HF~ J5H KOO KQ8 L7B MVM N4W N9A NEJ NHB OBH OCB OGEVE OHH OHT OMK OVD P-O P2P PQQKQ RAJ RNS SJN SKT SV3 TEORI TN5 UBY UHB UKR UMD UPT VH1 VVN WH7 WHG WOW X7M XHN XOL XSW XZL YFH YHZ YOC YPV YQJ YQT YQY YR2 YR5 YSK YYM YZZ ZCA ZCG ZGI ZXP 1CY 3O- 9M8 AAOGT AAQOH AAYJJ ABBLC ABDPE ACBNA ACCUC ACQAM ACTDY D0S EBD FA8 H13 IQODW QJJ S10 UAP UBC UHU WOQ XJT YQI YRY YXB YYQ ~H1 CGR CUY CVF ECM EIF GX1 NPM NYF OK1 PKN UIG YCJ YIF YIN ZKG 7X8 |
ID | FETCH-LOGICAL-a253t-389b1ef766e1cd70726da3df306d6c316b3d9aa03c58f259fd447f4d4ff0a1f93 |
ISSN | 0098-7484 1538-3598 |
IngestDate | Thu Sep 04 16:05:10 EDT 2025 Thu Feb 13 05:32:21 EST 2025 Mon Jul 21 09:16:40 EDT 2025 Wed Jun 25 03:37:35 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Human Cardiovascular disease Lipids Epidemiology Standards Vascular disease Medicine Apolipoprotein A Cholesterol HDL Atherosclerosis Risk factor Cardiovascular risk Adult Female Woman |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-a253t-389b1ef766e1cd70726da3df306d6c316b3d9aa03c58f259fd447f4d4ff0a1f93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 16030277 |
PQID | 68059777 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_68059777 pubmed_primary_16030277 pascalfrancis_primary_16948648 ama_primary_201250 |
PublicationCentury | 2000 |
PublicationDate | 2005-07-20 |
PublicationDateYYYYMMDD | 2005-07-20 |
PublicationDate_xml | – month: 07 year: 2005 text: 2005-07-20 day: 20 |
PublicationDecade | 2000 |
PublicationPlace | Chicago, IL |
PublicationPlace_xml | – name: Chicago, IL – name: United States |
PublicationTitle | JAMA : the journal of the American Medical Association |
PublicationTitleAlternate | JAMA |
PublicationYear | 2005 |
Publisher | American Medical Association |
Publisher_xml | – name: American Medical Association |
References | 16352785 - JAMA. 2005 Dec 14;294(22):2843-4; author reply 2844 16352786 - JAMA. 2005 Dec 14;294(22):2843; author reply 2844 |
References_xml | – reference: 16352786 - JAMA. 2005 Dec 14;294(22):2843; author reply 2844 – reference: 16352785 - JAMA. 2005 Dec 14;294(22):2843-4; author reply 2844 |
SSID | ssj0000137 |
Score | 2.410259 |
Snippet | CONTEXT Current guidelines for cardiovascular risk detection are controversial
with regard to the clinical utility of different lipid measures,... Current guidelines for cardiovascular risk detection are controversial with regard to the clinical utility of different lipid measures, non-high-density... |
SourceID | proquest pubmed pascalfrancis ama |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 326 |
SubjectTerms | Apolipoproteins - blood Atherosclerosis (general aspects, experimental research) Biological and medical sciences Biomarkers - blood Blood and lymphatic vessels C-Reactive Protein - metabolism Cardiology. Vascular system Cardiovascular Diseases - blood Cardiovascular Diseases - epidemiology Cholesterol - blood Female General aspects Humans Lipoproteins - blood Medical sciences Middle Aged Proportional Hazards Models Prospective Studies Risk Factors |
Title | Non–HDL Cholesterol, Apolipoproteins A-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women |
URI | http://dx.doi.org/10.1001/jama.294.3.326 https://www.ncbi.nlm.nih.gov/pubmed/16030277 https://www.proquest.com/docview/68059777 |
Volume | 294 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBASQoxruQw_8NZmSuLESR9Ly2gZ26DaxN4qJ46lSZBWtH3hf_An-RWc40viFtCAl6h1Y7fK-Xp8fPz5O4S8GgzSUqoUwFsqHiQqYkGexlkAM0vJ00SpguNB4ZNTPrlI3l2ml53OD4-1tFkXh-W3354r-R-rQhvYFU_J_oNlm0GhAV6DfeEKFobrX9n4dFEHk_H7HrowrXhgymUJrLywXGgJBmTADIOp3iN4HWFJ5lGbPoC7rmTvi0kTaoOaFo2KlSN2jmYfsBqNJqG78jxITiy3qax2qwcTKFrWYSvsBdfecxQST6zCO9fS7hntIga3g6bjY0PZQCZjm8GdTY-GUzNJyJZmPDo7O25mDo8RORuOP001reGtsOxnl-9IMZEahy1Cr_tR1tG3MqmNo49NOWWLaOa5bRZzLwJgRprjl8nFK2oAQx2yw6abr-K9M7s2nMeID5KcJ_kNcjPOIM5DAsHH3JM629Z3dQKjjUKW-0YnCXxnCfYVn5Wpv_LnBZIOlM7vkbt2hUOHBq77pFPV98mtE8vheEC-W9RSD7V9uoNZCpilAD6KmO1Th1iq8UkdYvv2vcFrX3cAtFKxoohWatFKAa10G63UopVe1VSj9SG5OHpzPpoEtjhIIOKUrQMItIuoUvAkq6iUWZjFXAomFSyBJS9ZxAsmB0KErExzBWt8JZMkU4kE9xOKSA3YI7JXL-rqCaEc7pGocyRi3OYviyxRcR5XaYk5mzztkn144vOlkX-ZQ8gM64YuOdgyQPOxs3OXvHQWmYPLxn04UVeLzWrO8xBVH7MueWwM5fUNkUeQPb1u8GfkdvvfeE721l831QuIjtfFgYbVT_Uauh8 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Non-HDL+cholesterol%2C+apolipoproteins+A-I+and+B100%2C+standard+lipid+measures%2C+lipid+ratios%2C+and+CRP+as+risk+factors+for+cardiovascular+disease+in+women&rft.jtitle=JAMA+%3A+the+journal+of+the+American+Medical+Association&rft.au=RIDKER%2C+Paul+M&rft.au=RIFAI%2C+Nader&rft.au=COOK%2C+Nancy+R&rft.au=BRADWIN%2C+Gary&rft.date=2005-07-20&rft.pub=American+Medical+Association&rft.issn=0098-7484&rft.volume=294&rft.issue=3&rft.spage=326&rft.epage=333&rft_id=info:doi/10.1001%2Fjama.294.3.326&rft.externalDBID=n%2Fa&rft.externalDocID=16948648 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0098-7484&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0098-7484&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0098-7484&client=summon |